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Cytotoxic Lymphocyte Recognition Review
of HLA-E: Utilizing a Nonclassical
Window to Peer into Classical MHC
Non-TCR-Related MHC-Recognizing Receptors
Considerable interest was generated recently by analy-
ses identifying and characterizing novel sets of MHC
class I±recognizing receptors expressed on NK cells
and subsets of T cells (Burshtyn and Long, 1997; Co-
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lonna, 1997; Moretta and Moretta, 1997; Yokoyama,When one tugs at a single thing in nature, he finds it
1997; Lanier, 1998). These molecules provided a mecha-attached to the rest of the world.
nistic explanation for how NK cells, a subpopulationÐJohn Muir
of lymphocytes that can kill certain tumor cells, virus-
infected cells, and normal hematopoietic cells, can pref-
erentially kill targets lacking self±MHC class I molecules.
Specifically, a model emerged in which ªclass I±bearingT cell antigen receptors trigger cellular activation after
targetsº versus ªclass I±deficient targetsº have differentrecognition of MHC/peptide complexes. However, struc-
regulatory effects on NK cell activation (Ljunggren andturally distinct MHC-recognizing receptors expressed
Karre, 1990). Class I±bearing targets engage MHC-rec-on natural killer (NK) cells serve an opposite function.
ognizing inhibitory receptors, resulting in the preventionSpecifically, MHC class I recognition by these novel
of NK cell±mediated cytotoxicity. In contrast, classreceptors potently blocks theability of NKcells to initiate
I±deficient targets fail toengage the inhibitory receptors,cell-mediated cytotoxicity in vitro or in vivo. Therefore,
thus facilitating NK cellular activation and killing. Abun-normal MHC class I±bearing cells are relatively resistant
dant experimental data from both in vitro and in vivoto NK cell±mediated killing because of their ability to
experimental models support this proposed mechanismengage the NK cell inhibitory receptors. In contrast, ma-
and suggest that class I interactions with MHC-recog-lignant or virus-infected cells with reduced MHC class
nizing receptors on NK cells critically influence NK cellI on their cell surface may fail to engage the NK cell
function.inhibitory receptors and, therefore, can become more
Molecular analyses have identified three distinct typessusceptible to NK cell±mediated cytotoxicity.
of inhibitory MHC-recognizing receptors on NK cells.As different families of MHC-recognizing receptors on
First, rodent NK cells express receptors encoded by theNK cells became molecularly identified and character-
small Ly-49 gene family located in a region called theized, a paradox emerged. Whereas certain families of
ªNK gene complexº on chromosome 6 in mice and onthese receptors inhibit NK cell activation after directly
chromosome 4 in rats (Yokoyama and Seaman, 1993).interacting with classical MHC class I molecules, others
Ly-49 is a type II integral membrane protein with homol-
seem to sense the presence or absence of classical
ogy to the C-type lectins. The receptors are expressed
MHC without clear evidence for a direct interaction. This
as disulfide-linked homodimers, and studies to date
left unanswered the question as to how certain NK cells
suggest that different allelic forms recognize overlap-
can evaluate the expression of classical MHC on poten-
ping subsets of class Ia molecules. In addition, Ly-49
tial target cells without bearing receptors capable of
gene products are clonally distributed on subpopula-
binding these molecules. It now appears that the answer
tions of NK cells, resulting in individual NK cells that
to this question has come from an unexpected place. may or may not bear the inhibitory receptor for a specific
Specifically, recent studies suggest that human NK cells class Ia molecule. However, all murine NK cells are be-
bear inhibitory receptors capable of recognizing the lieved to have at least one form of MHC-recognizing
nonclassical MHC molecule HLA-E (Borrego et al., 1998; inhibitory receptor. Although functional human homo-
Braud et al., 1998b; Lee et al., 1998b). One of the most logs to murine Ly-49 have not been identified, a putative
striking features about HLA-E is that its predominant pseudogene hasbeen located in the human NK cell gene
ligands are signal sequence±derived peptides from clas- complex on chromosome 12 (p12.3±13.1) (Westgaard et
sical MHC class I molecules (Braud et al., 1997). Since al., 1998).
HLA-E surface expression depends on the availability Human NK cells express a second type of MHC-rec-
of these class I±derived signal sequences (Braud et al., ognizing receptor, the human killer cell inhibitory recep-
1998a; Lee et al., 1998a), immune recognition of HLA-E tors (KIRs) (Burshtyn and Long, 1997; Colonna, 1997;
represents an indirect mechanism for broadly assessing Moretta and Moretta, 1997; Lanier, 1998). KIRs are type I
classical MHC class I expression. glycoproteins that contain two or three immunoglobulin-
This review focuses principally on how recognition of like domains in their extracellular regions. Different p58
HLA-E enables NK cells to monitor the integrity of the KIRs, all with two Ig domains, recognize subgroups of
MHC class I±dependent antigen presentation pathway. HLA-C class I molecules. The p70 KIRs with three Ig
Since certain subpopulations of activated cytotoxic T domains recognize a subset of HLA-B class I molecules.
lymphocytes (CTLs) can also express the HLA-E-recog- In addition, a homodimer of two p70 subunits is reported
nizing inhibitory receptors, experimental results are de- to recognize HLA-A molecules. Like Ly-49 receptors,
scribed regarding the effects of inhibitory receptors on different KIRs are clonally distributed onsubpopulations
CTL activation. Finally, the potential implications of of NK cellsand the repertoire of expressed KIR is hetero-
HLA-E recognition on antitumor immunity, antiviral im- geneous in different individuals.
A third type of MHC-recognizing inhibitory receptor,munity, and materno±fetal interactions are discussed.
Immunity
290
best characterized on human NK cells, is CD94/NKG2
(LoÂ pez-Botet et al., 1997; Lanier, 1998). This disulfide-
linked heterodimer contains two subunits with C-type
lectin homology. CD94 appears to be an invariant sub-
unit required for surface expression of NKG2. In con-
trast, several different NKG2 genes have been identified,
with theCD94/NKG2A complex being an identified inhib-
itory receptor. The CD94 and NKG2 genes are present
on human chromosome 12 (p 12.3±13.1) in the human
NK gene complex. Rodent CD94 has recently been iden-
tified and is located on the syntenic rat chromosome 4
and mouse chromosome 6 (Dissen et al., 1997; Vance
et al., 1997; Ho et al., 1998). The MHC specificity of the
CD94/NKG2 complex will be discussed later in this text.
Although the three forms of inhibitory MHC-recogniz-
Figure 1. Inhibitory Receptor Recognition of Assembled HLA Class Iing receptors differ markedly in their extracellular region,
An amino-terminal leader sequence (black) directs the translocationthe structural basis for their inhibitory activity appears
of newly translated HLA-class I into the endoplasmic reticulum. Afterto have been conserved in their cytoplasmic tails (Bin-
endopeptidase-mediated cleavage of the leader sequences, class Ia
stadt et al., 1997; Burshtyn and Long, 1997; Renard et heavy chains (brick red) sequentially assemble with b2 microglobulin
al., 1997). Specifically, immunoreceptor tyrosine-based (gold) and a diverse array of TAP (green) transported peptides (gray).
inhibitory motifs (ITIMs) are present on the intracellular In contrast, class Ib HLA-E heavy chains (blue) that have associated
with b2 microglobulinbind to TAP-transported peptidesderived fromportion of inhibitory Ly-49 receptors, KIRs, and the
conserved class Ia leader sequences (or from HLA-G leader se-NKG2-A subunit of the CD94/NKG2A complex. Tyrosine
quence). After transport of MHC-peptide complexes to the cell sur-phosphorylation of the ITIMs results in the recruitment of
face, cytotoxic lymphocytes bearing specific Ig domain±containing
SH2 domain±containing phosphatases, including SHP-1. killer cell inhibitory receptors (KIRs) can recognize distinct subsets
Recruited SHP-1 inhibits proximal protein tyrosine ki- of HLA-A, -B, and -C, and cytotoxic lymphocytes bearing CD94/
nase activation, a requisite event for the initiation of NK NKG2 can recognize HLA-E.
cell±mediated cytotoxicity.
Even though this review has focused on the inhibitory the binding site, allowing a diverse array of binding
forms of the MHC-recognizing receptors, homologs (Madden, 1995). In addition, the allelic polymorphisms
have been identified in each case that have the poten- of the heavy chain are centered around the peptide-
tial to trigger activation. In each case, the activating binding groove, further increasing the diversity of pep-
homolog lacks any ITIM in its cytoplasmic domain, and, tides bound by class Ia molecules. These peptide-bind-
instead, has a charged residue in its transmembrane ing, ubiquitously-expressed class Ia molecules have the
domain that enables it to specifically bind to an immu- potential to be recognized by specialized receptors on
noreceptor tyrosine-based activation motif (ITAM)-con- T cells and NK cells.
taining subunit, DAP12 (Lanier et al., 1998a, 1998b; Nonclassical human HLA-E shares multiple features
Smith et al., 1998). Although cross-linking these recep- with class Ia molecules (Figure 1). The similar overall
tors can induce NK cell±mediated cytotoxicity in vitro, structure includes a heavy chain/b2 microglobulin/pep-
their biologic role in vivo remains to be determined. tide complex. Sequence homology between HLA-E and
HLA-A, -B, and -C varies between 50% and 90% (Koller
et al., 1988). The ubiquitous tissue distribution of HLA-E
Human HLA-E and Murine Qa-1 matches that of MHC class Ia (Wei and Orr, 1990; Lee
While the observations regarding MHC-recognizing re- et al., 1998b). However, there are notable differences
ceptors on NK cells were emerging, separate analyses between HLA-E and HLA-A, -B, and -C that suggest
were focused on determining structural and functional distinct biologic function. HLA-E has limited polymor-
differences between class Ia (classical) and class Ib phism (2 alleles identified) (Geraghty et al., 1992; Grims-
(nonclassical) MHC molecules. Classical MHC class I ley and Ober, 1997), and there are unique amino acid
structures include the association of a membrane-span- substitutions within the peptide-binding groove at highly
ning, polymorphic 45 kDa heavy chain with an invariant invariant positions that contribute to a restricted pep-
12 kDa light chain b2 microglobulin (Figure 1). Peptides tide-binding specificity (alanine at position 67, serine for
of 8±10 amino acids in length are generated in the cyto- threonine at position 143, and serine for tryptophan at
plasm by proteolytic degradation, subsequently moving position 147) (Soloski et al., 1995). The crystal structure
to the endoplasmic reticulum by a mechanism involving of HLA-E reveals a constellation of requirements for
a specific transporter associated with antigen pro- hydrophobicity,size, configuration,and hydrogenbond-
cessing (TAP) and then binding to class Ia molecules ing that leads to remarkably high peptide specificity
(Pamer and Cresswell, 1998). The a1 and a2 domains (O'Callaghan et al., 1998).
of the class Ia heavy chain form the peptide-binding What provided an extraordinary twist in our under-
groove (Bjorkman et al., 1987a, 1987b), and the three- standing of HLA-E was theobservation that the principal
dimensional structure of this site places constraints on ligands bound to HLA-E are peptides derived from the
just two or three amino acid positions in the peptide leader sequences of HLA class Ia molecules (Braud et
(anchor positions). Other than at these anchor positions, al., 1997). Human class I leader sequences are remark-
ably conserved, with the only major variations occurringthere is marked flexibility in the peptide specificity of
Review
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at P2 (methionine and threonine), P7 (leucine and valine), However, several groups grasped a subtlety to the
experimental model that had not been fully appreciatedand P8 (leucine, isoleucine, and valine). Methionine at
P2 is permissive, whereas threonine abrogates HLA-E before (Borrego et al., 1998; Braud et al., 1998b; Lee et
al., 1998b). First, they noted the reports indicating thatbinding (Braud et al., 1997, 1998a; Lee et al., 1998a).
Since allelic forms of HLA-A and HLA-C, and some significant HLA-E cell surface expression requires bind-
ing to class Ia±derived leader sequence peptides. There-HLA-B, have methionine at P2, leader sequences from
a broad range of HLA class Ia molecules are bound to fore, class Ia±deficient cell lines would not only lack
class Ia, but would also have minimal cell surface HLA-EHLA-E. In addition, the leader sequence from nonclassi-
cal HLA-G also binds well to HLA-E (Braud et al., 1997). expression. As a corollary, class Ia transfectants would
express not only the transfected gene product, butImportantly, significant cell surface expression of HLA-E
depends on binding to leader sequence±derived pep- would also up-regulate HLA-E expression if the trans-
fected gene coded for a leader sequence permissive fortides (Braud et al., 1998a; Lee et al., 1998a). Since intact
TAP function is required for the peptide/HLA-E interac- HLA-E binding. In fact, the specific class Ia transfectants
that appeared to be resistant to killing by the CD94/tion and peptides from the leader sequence of HLA-E
itself are not capable of binding, cell surface expression NKG21 NK clones were the class Ia genes whose leader
sequence±derived peptides had been shown to bindof HLA-E broadly reflects the integrity of the MHC class
Ia±dependent antigen presentation pathway. HLA-E. These observations are all consistent with the
notion that CD94/NKG2 recognizes HLA-E rather thanIn mice, the class Ib gene Qa-1 and its gene products
share multiple features with HLA-E (Soloski et al., 1995). class Ia molecules.
Three groups provided formal evidence suggestingThe gene has low allelic polymorphism, and Qa-1b mole-
cules are ubiquitously expressed. Qa-1b has the same that CD94/NKG2 recognizes, perhaps exclusively, HLA-E.
In order to demonstrate a direct CD94/NKG2-HLA-E in-unique amino acid substitutions in the peptide-binding
groove (positions 67, 143, and 147) that contribute to teraction, Braud and colleagues utilized tetramers in
which HLA-E and b2 microglobulin were folded with anrestricted binding specificity. Qa-1b cell surface expres-
sion requires TAP-dependent binding of peptides de- MHC leader sequence peptide (Braud et al., 1998b).
These tetramers selectively bound to normal cells bear-rived from the leader sequence of class Ia molecules
(Aldrich et al., 1994; DeCloux et al., 1997), and, in fact, ing CD94 (NK cells and a subset of T cells) and to cells
transfected with either CD94/NKG2-A/B (inhibitory re-Qa-1b will actually bind conserved class I leader pep-
tides derived from multiple mammalian species (Kurepa ceptor) or CD94/NKG2-C (activating receptor). In addi-
tion, two separate strategies were used to up-regulateet al., 1998). In contrast, its own leader sequence (three
amino acids shorter) will not bind to Qa-1b, allowing HLA-E expression on class Ia±deficient lines. One ap-
proach used synthetic peptides corresponding to theQa-1b cell surface expression, like that of HLA-E, to
broadly reflect whether the class Ia±dependent antigen leader sequences of permissive class Ia molecules (Bor-
rego et al., 1998). The other involved transfecting classpresentation pathway is intact. Qa-1/peptidecomplexes
can be recognized by TCR on T lymphocytes (Vidovic Ia-deficient cells with genes encoding chimeric proteins
that would enhance HLE expression (e.g., permissiveet al., 1989; Aldrich et al., 1994), but the precise role of
this form of recognition remains unclear. HLA-A2-derived signal sequence and the extracellular
portion of HLA-E) (Braud et al., 1998b; Lee et al., 1998b).
In each case, up-regulation of HLA-E expression con-CD94/NKG2-Mediated Recognition of HLA-E
As alluded to earlier in the text, results from the initial ferred resistance against CD94/NKG2A-bearing NK cells.
Neutralizing antibody specific for either HLA-E or CD94/attempts to define the MHC specificity of the CD94/
NKG2 complex were quite confounding. Most of the NKG2 restored lysis. Taken together, these data clearly
suggest that HLA-E complexed with specific peptidesexperimental approaches involved comparing the sus-
ceptibility of class Ia±deficient cell lines versus specific from class Ia±derived leader sequences acts as a major
ligand for inhibitory CD94/NKG2-A (Figure 1). The roleclass Ia transfectants to NK cell±mediated cytotoxicity.
The premise was that if an NK clone bearing inhibitory of HLA-E recognition on NK cells bearing the activating
CD94/NKG2-C is less clear. The HLA-E tetramers doCD94/NKG2 could kill the class Ia±deficient cell line but
bind CD94/NKG2-C-bearing cells (Braud et al., 1998b).was unable to kill a specific class Ia transfectant, this
Furthermore, cells expressing HLA-E bound to leader se-would suggest that theCD94/NKG2 recognized that par-
quences derived from the class Ib molecule HLA-G canticular MHC class Ia molecule. This assumption would
induce killing by CD94/NKG2-C-bearing NK cells (Llanobe further supported if anti-CD94-specific antibody
et al., 1998). Interestingly, this induction of killing isused to block a CD94/NKG2-MHC interaction reversed
markedly less effective for HLA-E bound to leader se-the resistant phenotype. Using this approach, results
quences from class Ia molecules. Therefore, how differ-suggested that CD94/NKG2 could recognize most, but
ent NKG2 family members influence MHC-specificity,not all, allelic forms of HLA-A, -B, -C, and -G (Pazmany
the role of different leader sequence peptides in NK cellet al., 1996; Phillips et al., 1996; Sivori et al., 1996).
recognition, and the physiologic in vivo consequencesWhat was troubling was the absence of any common
of HLA-E recognition by activating CD94/NKG2 recep-structural feature in the extracellular domains of the
tors all remain to be determined.protective MHC that differentiated them from the non-
protective MHC. In addition, predictions that certain
antibodies specific for class I MHC would reverse the CD94/NKG2 and NK Cell Function
HLA-E recognition by CD94/NKG2 could potentiallyresistant phenotype by blocking a CD94/NKG2-MHC
interaction were not borne out. serve many functions. NK cells bearing these receptors
Immunity
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could provide potent defense against tumor cells with interactions enhances allospecific cytolytic activity. These
observations raise the possibility that depending on thereduced class Ia expression or against viruses that
down-regulate class Ia expression by transcriptional cytokine milieu in a localized inflammatory reaction, in-
hibitory CD94/NKG2-A receptors may be induced onmechanisms, altering heavy chain stability or interfering
with TAP function. The resultant reduction in the avail- CTLs, with the subsequent down-regulation of their cy-
tolytic activity. Since the leader sequences from manyability of class Ia±derived peptide should reduce cell
surface HLA-E expression, resulting in potential in- HLA class I molecules can bind to HLA-E and, therefore,
induce its expression, many CD94/NKG2-bearing CTLs,creased susceptibility to NK cells bearing inhibitory
CD94-NKG2-A receptors. Further work will be needed to irrespective of the MHC-specificity of their TCR, could
undergo this suppressed function. Importantly, it re-determine if viruses have evolved an escape mechanism
whereby their induced decrease in class Ia expression mains to be determined what other cytokines affect
CD94/NKG2 expression and whether certain pathologicis coupled to the coding for peptides that could bind
to HLA-E and therefore restore HLA-E expression. If forms of immunosuppression (e.g., tumor-bearing indi-
viduals) or specific autoimmune diseases involve theso, one potential reason for having both class Ia±rec-
ognizing inhibitory receptors (e.g., human KIRs and mu- inappropriate presence or absence of CD94/NKG2 on
CTL, respectively.rine Ly-49) and class Ib±recognizing inhibitory CD94-
NKG2-A would be to provide ongoing defense against
viruses of this kind. Concluding Remarks
In addition, since peptides from HLA-G leader se- The striking experimental observations summarized in
quences also bind HLA-E, CD94/NKG2 expression by this review reveal a novel mechanism whereby a recep-
uterine decidual NK cells could affect materno±fetal in- tor that binds to a highly specific ligand can be utilized
teractions. HLA-G is the predominant class I molecule to broadly assess complex and heterogeneous cellular
expressed on fetally derived placental trophoblast cells, functions. Specifically, CD94/NKG2-mediated recogni-
with extravillous cytotrophoblasts expressing high lev- tion of HLA-E enables cytotoxic lymphocytes to deter-
els of HLA-G upon their entry into the maternal decidua. mine whether potential targets have defects in any one
If HLA-G biosynthesis results in the expression of of multiple possible steps in the antigen/MHC class I
HLA-E, maternally derived cytotoxic lymphocytes bear- presentation pathway. Other receptors have evolved
ing inhibitory CD94/NKG2 could be prevented from in- that are capable of directly binding specific subgroups
teracting with the semiallogeneic trophoblasts. Alterna- of MHC class Ia molecules (e.g., human Ig domain±
tively, lymphocytes bearing activating CD94/NKG2 could containing KIRs and rodent Ly-49). However, since func-
block trophoblast infiltration into sites where these cells tional MHC-recognizing homologs for KIRs and Ly-49
would reside. The above described functions could pro- have not been identified broadly across species, these
vide the kind of selective advantage that would account receptors may represent somewhat specialized adapta-
for the remarkably high degree of evolutionary conserva- tions. In contrast, the striking conservation across spe-
tion for the expression of HLA-E homologs. cies of CD94/NKG2 and of MHC class Ib molecules
bearing signal sequence peptides derived from MHC
class Ia molecules indicates that their interaction sub-
CD94/NKG2 and CTL Activation serves critical, conserved biologic roles. Exploring their
The major focus in this review has been on the role of implications to antitumor immunity, antiviral immunity,
CD94/NKG2 on NK cellular activation. However, several autoimmunity, materno±fetal interactions, and lympho-
recent observations raise the possibility that activation- cyte homeostasis should provide new insights as to their
induced expression of CD94/NKG2 on a subset of CTLs critical regulatory functions.
may also critically influence CTL function (Mingari et al.,
1998a). Investigators had previously noted that a small
Acknowledgments
fraction of normal T cells bearing either TCRab or TCRgd
expresses KIRs or CD94 on the cell surface (Moretta et I want to thank Lewis Lanier, Miguel LoÂ pez-Botet, Lorenzo Moretta,
and James Forman for sharing with me prepublication manuscripts.al., 1990; Aramburu et al., 1991). Additional analyses
I also want to thank Larry Pease for his helpful discussions andindicated that the majority of this T cell subset is CD81
Bryce Binstadt and Kathy Brumbaugh for their critical reviews ofand has a phenotype consistent with memory T cells
the manuscript.(high levels of CD18, CD29, CD57, and CD45RO and an
absence of CD28) (Mingari et al., 1996, 1997). Further-
References
more, cross-linking KIRs or CD94/NKG2 strongly inhibits
CTL-mediated cytotoxicity (Ferrini et al., 1994; Mingari Aldrich, C.J., DeCloux, A., Woods, A.S., Cotter, R.J., Soloski, M.J.,
et al., 1995; Phillips et al., 1995). These observations and Forman, J. (1994). Identification of a Tap-dependent leader
peptide recognized by alloreactive T cells specific for a class Ibraise the possibility that inhibitory MHC-recognizing re-
antigen. Cell 79, 649±658.ceptors could contribute to the down-regulation of a
Aramburu, J., Balboa, M.A., Izquierdo, M., and LoÂ pez-Botet, M.CTL response.
(1991). A novel functional cell surface dimer (Kp43) expressed byRecent analyses suggest that IL-15 induces the ex-
natural killer cells and g/d TCR1 T lymphocytes. II. Modulation of
pression of CD94/NKG2-A on a sizeable fraction of CTLs natural killer cytotoxicity by anti-Kp43 monoclonal antibody. J. Im-
responding to alloantigens or superantigens (Mingari et munol. 147, 714±721.
al., 1998b). The CD94/NKG2-expressing CTLs appear to Binstadt, B.A., Brumbaugh, K.M., and Leibson, P.J. (1997). Signal
be inhibited in their cytolytic capability, since CD94-spe- transduction by human NK cell MHC-recognizing receptors. Immu-
nol. Rev. 155, 197±203.cific antibody used to block potential CD94/NKG2-MHC
Review
293
Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., Strom- the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad.
inger, J.L., and Wiley, D.C. (1987a). Structure of the human class I Sci. USA 95, 5199±5204.
histocompatibility antigen, HLA A2. Nature 329, 506±512. Ljunggren, H.-G., and KaÈ rre, K. (1990). In search of the ªmissing
Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., Strom- selfº: MHC molecules and NK cell recognition. Immunol. Today 11,
inger, J.L., and Wiley, D.C. (1987b). The foreign antigen binding site 237±244.
and T cell recognition regions of class I histocompatibility antigens. Llano, M., Lee, N., Navarro, F., Garcia, P., Albar, J.P., Geraghty,
Nature 329, 512±518. D.E., and LoÂ pez-Botet, M. (1998). HLA-E-bound peptides influence
Borrego, F., Ulbrecht, M., Weiss, E.H., Coligan, J.E., and Brooks, recognition by inhibitory and triggering CD94/NKG2 receptors: pref-
A.G. (1998). Recognition of human histocompatibility leukocyte anti- erential response to an HLA-G-derived nonamer. Eur. J. Immunol.,
gen (HLA)-E complexed with HLA class I signal sequence-derived in press.
peptides by CD94/NKG2 confers protection from natural killer cell- LoÂ pez-Botet, M., Perez-Villar, J.J., Carretero, M., Rodriguez, A., Mel-
mediated lysis. J. Exp. Med. 187, 813±818. ero, I., Bellon, T., Llano, M., and Navarro, F. (1997). Structure and
Braud, V., Jones, E.Y., and McMichael, A. (1997). The human major function of the CD94 C-type lectin receptor complex involved in
histocompatibility complex class Ib molecule HLA-E binds signal recognition of HLA class I molecules. Immunol. Rev. 155, 165±174.
sequence-derived peptides with primary anchor residues at posi- Madden, D.R. (1995). The three-dimensional structure of peptide-
tions 2 and 9. Eur. J. Immunol. 27, 1164±1169. MHC complexes. Annu. Rev. Immunol. 13, 587±622.
Braud, V.M., Allan, D.S.J., Wilson, D., and McMichael, A.J. (1998a). Mingari, M.C., Vitale, C., Cambiaggi, A., Schiavetti, F., Melioli, G.,
TAP- and tapasin-dependent HLA-E surface expression correlates Ferrini, S., and Poggi, A. (1995). Cytolytic T lymphocytes displaying
with the binding of an MHC class I leader peptide. Curr. Biol. 8, natural killer (NK)-like activity: expression of NK-related functional
1±10. receptors for HLA class I molecules (p58 and CD94) and inhibitory
Braud, V.M., Allan, D.S., O'Callaghan, C.A., SoÈ derstroÈ m, K., D'An- effect on the TCR-mediated target cell lysis or lymphokine produc-
drea, A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.I., Phillips, J.H., tion. Int. Immunol. 7, 697±703.
et al. (1998b). HLA-E binds to natural killer cell receptors CD94/ Mingari, M.C., Schiavetti, F., Ponte, M., Vitale, C., Maggi, E., Romag-
NKG2A, B and C. Nature 391, 795±799. nani, S., Demarest, J., Pantaleo, G., Fauci, A.S., and Moretta, L.
Burshtyn, D.N., and Long, E.O. (1997). Regulation through inhibitory (1996). Human CD81 T lymphocyte subsets that express HLA class
receptors: lessons from natural killer cells. Trends Cell Biol. 7, I-specific inhibitory receptors represent oligoclonally or mono-
473±479. clonally expanded cell populations. Proc. Natl. Acad. Sci. USA 93,
Colonna, M. (1997). Specificity and function of immunoglobulin su- 12433±12438.
perfamily NK cell inhibitory and stimulatory receptors. Immunol. Mingari, M.C., Ponte, M., Cantoni, C., Vitale, C., Schiavetti, F., Ber-
Rev. 155, 127±133. tone, S., Bellomo, R., Cappai, A.T., and Biassoni, R. (1997). HLA-
DeCloux, A., Woods, A.S., Cotter, R.J., Soloski, M.J., and Forman, class I-specific inhibitory receptors in human cytolytic T lympho-
J. (1997). Dominance of a single peptide bound to the class IB cytes: molecular characterization, distribution in lymphoid tissues
molecule, Qa-1b. J. Immunol. 158, 2183±2191. and co-expression by individual T cells. Int. Immunol. 9, 485±491.
Dissen, E., Berg, S.F., Westgaard, I.H., and Fossum, S. (1997). Mo- Mingari, M.C., Moretta, A., and Moretta, L. (1998a). Regulation of
lecular characterization of a gene in the rat homologous to human KIR expression in human T cells: a safety mechanism that may
CD94. Eur. J. Immunol. 27, 2080±2086. impair protective T-cell responses. Immunol. Today 19, 153±157.
Ferrini, S., Cambiaggi, A., Meazza, R., Sforzini, S., Marciano, S., Mingari, M.C., Ponte, M., Bertone, S., Schiavetti, F., Vitale, C., Bel-
Mingari, M.C., and Moretta, L. (1994). T cell clones expressing the lomo, R., Moretta, A., and Moretta, L. (1998b). HLA class I-specific
natural killer cell-related p58 receptor molecule display heterogene- inhibitory receptors in human T lymphocytes: interleukin 15-induced
ity in phenotypic properties and p58 function. Eur. J. Immunol. 24, expression of CD94/NKG2A in superantigen- or alloantigen-acti-
2294±2298. vated CD81 T cells. Proc. Natl. Acad. Sci. USA 95, 1172±1177.
Geraghty, D.E., Stockschleader, M., Ishitani, A., and Hansen, J.A. Moretta, A., and Moretta, L. (1997). HLA class I specific inhibitory
(1992). Polymorphism at the HLA-E locus predates most HLA-A receptors. Curr. Opin. Immunol. 9, 694±701.
and -B polymorphism. Hum. Immunol. 33, 174±184. Moretta, A., Tambussi, G., Bottino, C., Tripodi, G., Merli, A., Ciccone,
Grimsley, C., and Ober, C. (1997). Population genetic studies of E., Pantaleo, G., and Moretta, L. (1990). A novel surface antigen
HLA-E. Evidence for selection. Hum. Immunol. 52, 33±40. expressed by a subset of human CD32CD161 natural killer cells.
Role in cell activation and regulation of cytolytic function. J. Exp.Ho, E.L., Heusel, J.W., Brown, M.G., Matsumoto, K., Scalzo, A.A.,
Med. 171, 695±714.and Yokoyama, W.M. (1998). Murine NKG2D and CD94 are clustered
within the natural killer complex and are expressed independently O'Callaghan, C.A., Tormo, J., Willcox, B.E., Braud, V.M., Jakobsen,
in natural killer cells. Proc. Natl. Acad. Sci. USA 95, 6320±6325. B.K., Stuart, D.I., McMichael, A.J., Bell, J.I., and Jones, E.Y. (1998).
Koller, B.H., Geraghty, D.E., Shimizu, Y., DeMars, R., and Orr, H.T. Structural features impose tight peptide binding specificity in the
(1988). HLA-E. A novel HLA class I gene expressed in resting T nonclassical MHC molecule HLA-E. Mol. Cell 1, 531±541.
lymphocytes. J. Immunol. 141, 897±904. Pamer, E., and Cresswell, P. (1998). Mechanisms of MHC class
Kurepa, Z., Hasemann, C., and Forman, J. (1998). Qa-1b binds con- I-restricted antigen presentation. Annu. Rev. Immunol. 16, 323±358.
served class I leader peptides derived from several mammalian Pazmany, L., Mandelboim, O., ValeÂ s-GoÂ mez, M., Davis, D.M., Rey-
species. J. Exp. Med., in press. burn, H.T., and Strominger, J.L. (1996). Protection from natural killer
Lanier, L.L. (1998). NK cell receptors. Annu. Rev. Immunol. 16, cell-mediated lysis by HLA-G expression on target cells. Science
359±393. 274, 792±795.
Lanier, L.L., Corliss, B.C.,Wu, J., Leong,C., and Phillips, J.H. (1998a). Phillips, J.H., Gumperz, J.E., Parham, P., and Lanier, L.L. (1995).
Immunoreceptor DAP12 bearing a tyrosine-based activation motif Superantigen-dependent, cell-mediated cytotoxicity inhibited by
is involved in activating NK cells. Nature 391, 703±707. MHC class I receptors on T lymphocytes. Science 268, 403±405.
Lanier, L.L., Corliss, B., Wu, J., and Phillips, J.H. (1998b). Association Phillips, J.H., Chang, C., Mattson, J., Gumperz, J.E., Parham, P.,
of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity and Lanier, L.L. (1996). CD94 and a novel associated protein (94AP)
8, 693±701. form a NK cell receptor involved in the recognition of HLA-A, HLA-B,
and HLA-C allotypes. Immunity 5, 163±172.Lee, N., Goodlett, D.R., Ishitani, A., Marquardt, H., and Geraghty,
D.E. (1998a). HLA-E surface expression depends on binding of TAP- Renard, V., Cambiaggi, A., Vely, F., Blery, M., Olcese, L., Olivero,
dependent peptides derived from certain HLA class I signal se- S., Bouchet, M., and Vivier, E. (1997). Transduction of cytotoxic
quences. J. Immunol. 160, 4951±4960. signals in natural killer cells: a general model of fine tuning between
activatory and inhibitory pathways in lymphocytes. Immunol. Rev.Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., LoÂ pez-
Botet, M., and Geraghty, D.E. (1998b). HLA-E is a major ligand for 155, 205±221.
Immunity
294
Sivori, S., Vitale, M., Bottino, C., Marcenaro, E., Sanseverino, L.,
Parolini, S., Moretta, L., and Moretta, A. (1996). CD94 functions as
a natural killer cell inhibitory receptor for different HLA class I alleles:
identification of the inhibitory form of CD94 by the use of novel
monoclonal antibodies. Eur. J. Immunol. 26, 2487±2492.
Smith, K.M., Wu, J., Bakker, A.B., Phillips, J.H., and Lanier, L.L.
(1998). Ly-49D and Ly-49H associate with mouse DAP12 and form
activating receptors. J. Immunol. 161, 7±10.
Soloski, M.J., DeCloux, A., Aldrich, C.J., and Forman, J. (1995).
Structural and functional characteristics of the class IB molecule,
Qa-1. Immunol. Rev. 147, 67±89.
Vance, R.E., Tanamachi, D.M., Hanke, T., and Raulet, D.H. (1997).
Cloning of a mouse homolog of CD94 extends the family of C-type
lectins on murine natural killer cells. Eur. J. Immunol. 27, 3236±3241.
Vidovic, D., Roglic, M., McKune, K., Guerder, S., MacKay, C., and
Dembic, Z. (1989). Qa-1 restricted recognition of foreign antigen by
a gamma delta T-cell hybridoma. Nature 340, 646±650.
Wei, X.H., and Orr, H.T. (1990). Differential expression of HLA-E,
HLA-F, and HLA-G transcripts in human tissue. Hum. Immunol. 29,
131±142.
Westgaard, I.H., Berg, S.F., érstavik, S., Fossum, S., and Dissen, E.
(1998). Identification of a human member of the Ly-49 multigene
family. Eur. J. Immunol. 28, 1839±1846.
Yokoyama, W.M. (1997). What goes up must come down: the emerg-
ing spectrum of inhibitory receptors. J. Exp. Med. 186, 1803±1808.
Yokoyama, W.M., and Seaman, W.E. (1993). The Ly-49 and NKR-
P1 gene families encoding lectin-like receptors on natural killer cells:
the NK gene complex. Annu. Rev. Immunol. 11, 613±635.
